Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145062 | 0.89 | — | — | |
| SCHEMBL12132241 | 0.89 | — | — | |
| SCHEMBL8297623 | 0.78 | — | — | |
| SCHEMBL10143226 | 0.78 | — | — | |
| SCHEMBL10145060 | 0.78 | — | — | |
| SCHEMBL12132242 | 0.78 | — | — | |
| SCHEMBL12132349 | 0.76 | KMT2A (0.39) | CYP1A2MGLLPHGDHALDH1A1HTT | |
| SCHEMBL24051546 | 0.76 | CYP1A2 (0.46) | CYP1A2TDP1MGLLPHGDHHTR1A | |
| SCHEMBL10145581 | 0.76 | KMT2A (0.39) | CYP1A2MGLLPHGDHALDH1A1HTT | |
| SCHEMBL17236510 | 0.72 | SMN1; SMN2 (0.50) | MGLLPHGDHALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | SLC6A4, SLC1A2, SLC6A2 | CYP1A2 499/4885TDP1 1806/4885MGLL 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.